XML 69 R59.htm IDEA: XBRL DOCUMENT v3.26.1

Research and Development Funding Expense - R&D Funding Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total Commitments	$ 825,000
Unfunded Commitments	600,000
Research and development funding expense	39,790	$ 50,500
Phase 2b, TEV-408
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development funding expense	14,300
Johnson & Johnson | JNJ‑4804
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total Commitments	500,000
Unfunded Commitments	500,000
Teva Pharmaceuticals | Total Funding, TEV-408
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total Commitments	75,000
Unfunded Commitments	75,000
Research and development commitment	500,000
Teva Pharmaceuticals | Phase 2b, TEV-408
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development commitment	75,000
Teva Pharmaceuticals | Phase 3, TEV-408
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development commitment	425,000
Biogen | Litifilimab
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total Commitments	250,000
Unfunded Commitments	$ 25,000

X

- Definition

Research and Development Commitment

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentCommitment
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Research And Development Commitments

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentCommitments
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Research And Development Unfunded Commitments

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentUnfundedCommitments
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=rprx_Phase2bTEV408Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_JohnsonAndJohnsonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=rprx_JNJ4804Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_TevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=rprx_TotalFundingTEV408Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=rprx_Phase3TEV408Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=rprx_BiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=rprx_LitifilimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: